6 Comments
User's avatar
William Poundstone's avatar

And as the cost of the drugs fall...

I do hope future versions will have fewer side effects

Mallard's avatar
1hEdited

You may want to clarify which sources are being used in figure 1. E.g. the graphic uses 3 colors, but the key doesn't include yellow. I'm guessing that yellow and blue are a single source, but even after following the link to the discussion of the Economist, I'm still not sure.

You may also want to create an updated version of the chart here: https://x.com/cremieuxrecueil/status/1991567890613694888, with newer data for Retatrutide.

Phase 2 results for VK2735 have now been published, as well: https://onlinelibrary.wiley.com/doi/10.1002/oby.70106.

Topline results were also announced for PF-08653944: https://www.pfizer.com/news/press-release/press-release-detail/pfizers-ultra-long-acting-injectable-glp-1-ra-shows-robust, as well as newer ones for Survodutide: https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/glp-1-dual-agonist-survodutide-weightloss-obesity-overweight-improvement.

You could throw in Orforglipron, as well.

William Poundstone's avatar

I've lost 18 pounds on oral wegovy

Oliver's avatar

This isn't like asking about the effectiveness of antidepressants, creatine or new cancer drugs, this is the equivalent of comparing antibiotics to no treatment. The effects are huge and involve tens of millions of people.

jf's avatar

It's nice to read good news for once. Thank you!

Nate Pedersen's avatar

I bet by the end of trumps term, America will be measurably healthier. RFK and MAHA will try to take the credit, when in reality it will be due to GLP1-RAs